WO2014068585A1 - Novel lyophilized compositions of cyclophosphamide - Google Patents
Novel lyophilized compositions of cyclophosphamide Download PDFInfo
- Publication number
- WO2014068585A1 WO2014068585A1 PCT/IN2013/000469 IN2013000469W WO2014068585A1 WO 2014068585 A1 WO2014068585 A1 WO 2014068585A1 IN 2013000469 W IN2013000469 W IN 2013000469W WO 2014068585 A1 WO2014068585 A1 WO 2014068585A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyclophosphamide
- atleast
- butanol
- acetate
- solvent
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 title claims description 73
- 229960004397 cyclophosphamide Drugs 0.000 title claims description 73
- 239000002904 solvent Substances 0.000 claims abstract description 61
- 238000000034 method Methods 0.000 claims abstract description 52
- 238000004108 freeze drying Methods 0.000 claims abstract description 40
- PWOQRKCAHTVFLB-UHFFFAOYSA-N cyclophosphamide hydrate Chemical group O.ClCCN(CCCl)P1(=O)NCCCO1 PWOQRKCAHTVFLB-UHFFFAOYSA-N 0.000 claims abstract description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 87
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 81
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 76
- 238000001035 drying Methods 0.000 claims description 51
- 239000000243 solution Substances 0.000 claims description 41
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 35
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 239000011877 solvent mixture Substances 0.000 claims description 23
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 18
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 18
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 18
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 18
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 16
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 15
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 12
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 12
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 12
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 12
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 claims description 12
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 12
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 claims description 12
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims description 10
- 238000007710 freezing Methods 0.000 claims description 10
- 230000008014 freezing Effects 0.000 claims description 10
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 10
- 239000012535 impurity Substances 0.000 claims description 9
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 claims description 8
- 238000012792 lyophilization process Methods 0.000 claims description 8
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 7
- KFUSEUYYWQURPO-UHFFFAOYSA-N 1,2-dichloroethene Chemical compound ClC=CCl KFUSEUYYWQURPO-UHFFFAOYSA-N 0.000 claims description 6
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 claims description 6
- QQZOPKMRPOGIEB-UHFFFAOYSA-N 2-Oxohexane Chemical compound CCCCC(C)=O QQZOPKMRPOGIEB-UHFFFAOYSA-N 0.000 claims description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- 229960000583 acetic acid Drugs 0.000 claims description 6
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 6
- 229940093499 ethyl acetate Drugs 0.000 claims description 6
- 235000019439 ethyl acetate Nutrition 0.000 claims description 6
- 229940093476 ethylene glycol Drugs 0.000 claims description 6
- 235000019253 formic acid Nutrition 0.000 claims description 6
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 6
- VBZWSGALLODQNC-UHFFFAOYSA-N hexafluoroacetone Chemical compound FC(F)(F)C(=O)C(F)(F)F VBZWSGALLODQNC-UHFFFAOYSA-N 0.000 claims description 6
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 claims description 6
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 6
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 claims description 6
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 6
- 229940011051 isopropyl acetate Drugs 0.000 claims description 6
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 6
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 claims description 6
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 claims description 6
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 claims description 6
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 claims description 6
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 claims description 6
- 229940090181 propyl acetate Drugs 0.000 claims description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 6
- 239000013557 residual solvent Substances 0.000 claims description 6
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 6
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 claims description 5
- 229940093475 2-ethoxyethanol Drugs 0.000 claims description 5
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 5
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 5
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 5
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 claims description 5
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 claims description 5
- 229940090044 injection Drugs 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- -1 2-EthcfKyethanol Chemical compound 0.000 claims description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 4
- 238000000137 annealing Methods 0.000 claims description 4
- 229960004926 chlorobutanol Drugs 0.000 claims description 4
- 239000006185 dispersion Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000008096 xylene Substances 0.000 claims description 4
- XUKUURHRXDUEBC-SXOMAYOGSA-N (3s,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SXOMAYOGSA-N 0.000 claims description 3
- AAEQXEDPVFIFDK-UHFFFAOYSA-N 3-(4-fluorobenzoyl)-2-(2-methylpropanoyl)-n,3-diphenyloxirane-2-carboxamide Chemical compound C=1C=CC=CC=1NC(=O)C1(C(=O)C(C)C)OC1(C=1C=CC=CC=1)C(=O)C1=CC=C(F)C=C1 AAEQXEDPVFIFDK-UHFFFAOYSA-N 0.000 claims description 3
- 229940108605 cyclophosphamide injection Drugs 0.000 claims description 3
- 235000011007 phosphoric acid Nutrition 0.000 claims description 3
- 238000001121 post-column derivatisation Methods 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 2
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 claims description 2
- 229940032007 methylethyl ketone Drugs 0.000 claims description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 15
- RWGFKTVRMDUZSP-UHFFFAOYSA-N cumene Chemical compound CC(C)C1=CC=CC=C1 RWGFKTVRMDUZSP-UHFFFAOYSA-N 0.000 claims 10
- 229960004592 isopropanol Drugs 0.000 claims 9
- 229940044613 1-propanol Drugs 0.000 claims 5
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims 5
- 235000011054 acetic acid Nutrition 0.000 claims 5
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 5
- 238000004445 quantitative analysis Methods 0.000 claims 5
- 229960004756 ethanol Drugs 0.000 claims 4
- 238000004007 reversed phase HPLC Methods 0.000 claims 4
- 238000013375 chromatographic separation Methods 0.000 claims 3
- 239000012470 diluted sample Substances 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- UBOXGVDOUJQMTN-UHFFFAOYSA-N 1,1,2-trichloroethane Chemical compound ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 239000000047 product Substances 0.000 description 23
- 229940079593 drug Drugs 0.000 description 22
- 239000003814 drug Substances 0.000 description 22
- 238000009472 formulation Methods 0.000 description 20
- 150000004682 monohydrates Chemical class 0.000 description 19
- 238000002156 mixing Methods 0.000 description 18
- 239000000523 sample Substances 0.000 description 18
- 239000003085 diluting agent Substances 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 239000008186 active pharmaceutical agent Substances 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 10
- 229940088679 drug related substance Drugs 0.000 description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 9
- 229930195725 Mannitol Natural products 0.000 description 9
- 239000000594 mannitol Substances 0.000 description 9
- 235000010355 mannitol Nutrition 0.000 description 9
- 239000008364 bulk solution Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000008103 glucose Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000004067 bulking agent Substances 0.000 description 4
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 4
- 229940126534 drug product Drugs 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 239000012086 standard solution Substances 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000001073 sample cooling Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 239000008181 tonicity modifier Substances 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- OAGWWSLERUWMBK-UHFFFAOYSA-N acetonitrile;propan-2-one;hydrate Chemical compound O.CC#N.CC(C)=O OAGWWSLERUWMBK-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 229940113088 dimethylacetamide Drugs 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012957 stability-indicating analytical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- BIIBYWQGRFWQKM-JVVROLKMSA-N (2S)-N-[4-(cyclopropylamino)-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl]-2-[[(E)-3-(2,4-dichlorophenyl)prop-2-enoyl]amino]-4,4-dimethylpentanamide Chemical compound CC(C)(C)C[C@@H](C(NC(C[C@H](CCN1)C1=O)C(C(NC1CC1)=O)=O)=O)NC(/C=C/C(C=CC(Cl)=C1)=C1Cl)=O BIIBYWQGRFWQKM-JVVROLKMSA-N 0.000 description 1
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- NYNZQNWKBKUAII-KBXCAEBGSA-N (3s)-n-[5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide Chemical compound C1[C@@H](O)CCN1C(=O)NC1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 NYNZQNWKBKUAII-KBXCAEBGSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BNNZCELZKQKDQY-UHFFFAOYSA-N 1,3,2-oxazaphosphinan-2-ium 2-oxide Chemical compound O=[P+]1NCCCO1 BNNZCELZKQKDQY-UHFFFAOYSA-N 0.000 description 1
- BGJSXRVXTHVRSN-UHFFFAOYSA-N 1,3,5-trioxane Chemical compound C1OCOCO1 BGJSXRVXTHVRSN-UHFFFAOYSA-N 0.000 description 1
- DILISPNYIVRDBP-UHFFFAOYSA-N 2-[3-[2-(2-hydroxypropylamino)pyrimidin-4-yl]-2-naphthalen-2-ylimidazol-4-yl]acetonitrile Chemical compound OC(CNC1=NC=CC(=N1)N1C(=NC=C1CC#N)C1=CC2=CC=CC=C2C=C1)C DILISPNYIVRDBP-UHFFFAOYSA-N 0.000 description 1
- DWKNOLCXIFYNFV-HSZRJFAPSA-N 2-[[(2r)-1-[1-[(4-chloro-3-methylphenyl)methyl]piperidin-4-yl]-5-oxopyrrolidine-2-carbonyl]amino]-n,n,6-trimethylpyridine-4-carboxamide Chemical compound CN(C)C(=O)C1=CC(C)=NC(NC(=O)[C@@H]2N(C(=O)CC2)C2CCN(CC=3C=C(C)C(Cl)=CC=3)CC2)=C1 DWKNOLCXIFYNFV-HSZRJFAPSA-N 0.000 description 1
- UXHQLGLGLZKHTC-CUNXSJBXSA-N 4-[(3s,3ar)-3-cyclopentyl-7-(4-hydroxypiperidine-1-carbonyl)-3,3a,4,5-tetrahydropyrazolo[3,4-f]quinolin-2-yl]-2-chlorobenzonitrile Chemical compound C1CC(O)CCN1C(=O)C1=CC=C(C=2[C@@H]([C@H](C3CCCC3)N(N=2)C=2C=C(Cl)C(C#N)=CC=2)CC2)C2=N1 UXHQLGLGLZKHTC-CUNXSJBXSA-N 0.000 description 1
- HFGHRUCCKVYFKL-UHFFFAOYSA-N 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5h-pyrimido[5,4-b]indole Chemical compound C1=C2NC=3C(OCC)=NC(N4CCNCC4)=NC=3C2=CC=C1C1=CC=NC=C1 HFGHRUCCKVYFKL-UHFFFAOYSA-N 0.000 description 1
- SJVGFKBLUYAEOK-SFHVURJKSA-N 6-[4-[(3S)-3-(3,5-difluorophenyl)-3,4-dihydropyrazole-2-carbonyl]piperidin-1-yl]pyrimidine-4-carbonitrile Chemical compound FC=1C=C(C=C(C=1)F)[C@@H]1CC=NN1C(=O)C1CCN(CC1)C1=CC(=NC=N1)C#N SJVGFKBLUYAEOK-SFHVURJKSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 240000003321 Mentha requienii Species 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- GPEHQHXBPDGGDP-UHFFFAOYSA-N acetonitrile;propan-2-one Chemical compound CC#N.CC(C)=O GPEHQHXBPDGGDP-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- KTUQUZJOVNIKNZ-UHFFFAOYSA-N butan-1-ol;hydrate Chemical group O.CCCCO KTUQUZJOVNIKNZ-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- GTSZJFSUYZICDS-UHFFFAOYSA-N n,n-bis(2-chloroethyl)-3-methyl-2-oxo-1,3,2$l^{5}-oxazaphosphinan-2-amine Chemical compound CN1CCCOP1(=O)N(CCCl)CCCl GTSZJFSUYZICDS-UHFFFAOYSA-N 0.000 description 1
- XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- KMIOJWCYOHBUJS-HAKPAVFJSA-N vorolanib Chemical compound C1N(C(=O)N(C)C)CC[C@@H]1NC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C KMIOJWCYOHBUJS-HAKPAVFJSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8872—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample impurities
Definitions
- Cyclophosphamide is a synthetic antineoplastic drug chemically related to the nitrogen mustards and has the following structure:
- cyclophosphamide 2-[bis(2-chloroethyI)amino]tetrahydro-2H- 1 ,3,2-oxazaphosphorine 2-oxide monohydrate.
- the compound along with related novel cyclic phosphoric acid ester amides was disclosed and claimed in U.S patent 3,018,302.
- Cyclophosphamide comprises of monohydrate and anhydrous forms.
- the monohydrate is a stable form but under dry conditions (relative humidities of about 20% or less) the monohydrate begins to lose this water of hydration which can cause problems in manufacture. Hence maintaining the manufacturing and storage temperatures for this product is extremely important.
- U.S patent 4,659,699 to Daniel et al. discloses the process for freeze drying of Cyclophosphamide.
- the two stage process described in the patent involves freeze drying of an aqueous solution of Cyclophosphamide to yield a hydrate of Cyclophosphamide.
- Cyclophosphamide is freeze dried with an excipient until the moisture content is less than 2% by weight.
- the freeze dried material is rehydrated until the moisture content of the product is in the critical range i.e 2-7% by weight.
- the process described in this patent requires the use of high quantity of excipients for maintaining the stability of the product.
- lyophilizates of Cyclophosphamide are prepared by lyophilizing a solution of Cyclophosphamide and one or more excipients and rehydrating the product such that it contains about 4% moisture.
- the lyophilizates described in this patent used various excipients like mannitol, sodium bicarbonate, lactose, polyvinyl pyrrolidone (PVP), arginine, and tartaric acid.
- Cyclophosphamide is available as monohydrate in parenteral dosage formulation consisting of sterile packaged dry powder blend mixtures of drug and sodium chloride. The premixes were dissolved in water prior to administration. During the processing and storage of dry powder premix formulation, a glassiness and or stickiness could be acquired by the premix composition giving unattractive material with inferior solubility characteristics and decreased potency.
- Another aspect of the present invention is to describe process for producing a stable lyophilized cyclophosphamide monohydrate formulation by using a suitable solvent or mixture of solvents in suitable proportions and optionally contains other excipients.
- Another aspect of the present invention is to develop formulations of Cyclophosphamide monohydrate with uniform hydrate integrity between the vials.
- Another aspect of the present invention is to provide Cyclophosphamide formulations with improved stability and lesser time for reconstitution.
- FIG. 1 shows the DSC thermogram of prelyophilizate comprising of Cyclophosphamide dissolved in mixture of Acetone-TBA-Water (35.17: 47.61 : 16.67%v/v).
- FIG 2 depicts Diffractogram of Cyclophosphamide drug and lyophilized product.
- FIG 3 depicts a DSC thermogram obtained for Cyclophosphamide drug and lyophilized product.
- FIG 4 depicts an IR spectra obtained for Cyclophosphamide drug and lyophilized product.
- the objective of the present invention is to prepare a stable lyophilized parenteral pharmaceutical compositions of cyclophosphamide monohydrate.
- An aspect of the present invention relates to the process for producing a stable lyophilized cyclophosphamide monohydrate formulation by using a suitable solvent or mixture of solvents in suitable proportions and optionally contains other excipients.
- Another aspect of the present invention is to describe lyophilization process for producing pharmaceutical compositions of cyclophosphamide monohydrate.
- a lyophilization process of cyclophosphamide injection comprises of following steps: (a) Dissolving or dispersing cyclophosphamide in organic solvents or mixtures thereof (b) Filling the solution or dispersion in vials (c) Freezing the solution or dispersion (d) drying.
- Another aspect of the present invention is to develop formulations of Cyclophosphamide monohydrate with uniform hydrate integrity between the vials and improved stability and lesser time for reconstitution.
- Another aspect of the present invention is to describe stability indicating analytical method to monitor drug product quality.
- the invention involves forming stable monohydrate "in situ" during lyophilization without the need for a rehydration step as taught in the prior art.
- This aspect of the invention is achieved by (i) a proper selection of solvent system and/ or (ii) optimal process conditions during the lyophilization process.
- the present invention discloses a process for manufacturing a lyophilized preparation of cyclophosphamide intended for use in parenteral administration.
- the pharmaceutical formulation of the invention comprises Cyclophosphamide monohydrate and at least one organic solvent or mixture of solvents to dissolve the drug. The solvent is later removed during the freeze drying process.
- the formulation additionally comprises water to facilitate the formation of the stable monohydrate form during lyophilization.
- Freeze drying process involves removal of solvent from a frozen mass under reduced atmospheric pressure.
- freeze drying drying and Lyophilization shall be used interchangeably. Lyophilization helps stabilize pharmaceutical formulations by reducing the solvent component or components to levels that no longer support chemical reactions or biological growth. Since drying during lyophilization takes place at a low temperature, chemical decomposition is also reduced. Annealing shall be defined as process of transient increase in product temperature from initial set point to higher or lower set point, and then bringing the product temperature back to original set point. Annealing can be done on product during different steps of freeze drying process.
- Frozen mass shall be defined as a product kept at temperature where in the physical state of the product changes from liquid to semi solid mass or solid mass.
- a frozen mass shall also mean a product kept at a temperature lower than zero degrees centigrade.
- Prelyophilizate shall mean a composition comprising cyclophosphamide dissolved or suspended in solvents and meant to be subjected to freeze drying.
- the prelyophilizate may comprise suitable pharmaceutically acceptable excipient selected from list of excipients as described in the present invention " The excipients or drug shall be in dissolved or suspended form in the solvent mixture.
- freeze-dried formulation or “Lyophilizate” shall be defined as a dried product obtained as a result of freeze drying or lyophilization or drying process using a freeze dryer.
- Freeze drying apparatus comprises of a chamber, condenser, and vacuum system with programmable features to control temperature and vacuum during drying process.
- the equipment optionally may have solvent trap.
- the injectable formulations of the present invention comprises pharmaceutically acceptable carrier.
- the pharmaceutically acceptable carrier or excipient can be selected from solvent, bulking agent, complexing agents, preservatives, anti-oxidants, stabilizers, tonicity modifiers or any other suitable adjuvant thereof.
- solvent refers to the liquid component of a formulation that is capable of dissolving or suspending one or more solutes.
- solvent can refer to a single solvent or a mixture of solvents.
- the solvent as mentioned, can be any liquid in which the material dissolves or could be suspended; the solvent can be a single substance or a mixture of co-solvents.
- Suitable solvents include the following, but are not limited to Acetone, Acetonitrile, Tertiary butanol, Methanol, Ethanol, Isopropyl alcohol, Ethylacetate, Toulene, Propyl acetate, Nitromethane, 1 ,4-Dioxane, Heptane, Methylcyclohexane, Formic acid, isopropyl acetate, 1 ,2-Dimethoxyethane, 1 , 1 ,2-Trichloroethene, Methylethyl ketone, Cyclohexane, Ethyl formate, Hexane, Tetrahydrofuran, Chloroform, Methyl acetate, 1 ,2-Dichloroethene, tert-Butylmethyl ether, Dichloromethane, Pentane, E
- the purpose of the bulking agent is to provide bulk to the formulation and enhance cake formation.
- Bulking agents include saccharides, preferably monosaccharides or oligosaccharides, sugar alcohols, and mixtures thereof.
- Suitable bulking agents include the following, but are not limited to mannitol, sodium chloride, glucose, sucrose, lactose, trehalose, dextrose, maltose, sorbitol, dextran, raffinose, PVP, histidine, amino acids such as glycine, arginine, aspartic acid and the like.
- Tonicity modifier can also be optionally added to the formulation. Suitable tonicity modifiers include the following, but are not limited to mannitol, dextrose, sucrose, glycine, glycerol, sodium chloride and the like.
- Stabilizing agents are typically added to a formulation to improve stability of the formulation.
- Suitable examples of stabilizing agents include cryoprotectants, lyoprotectants, crystallization inhibitors or any other suitable stabilizer thereof.
- Suitable stabilizers include the following, but are not limited to Saccharides, including monosaccharides such as glucose, disaccharides such as sucrose (glucose+fructose), lactose (glucose+galactose), maltose (glucose+glucose), and trehalose (alpha-D- glucopyranosyl alpha-D-glucopyranoside), and polysaccharides such as dextran (polysaccharide containing glucose monomers, Crystallization inhibitors such as PVP (polyvinylpyrrolidone), HPC (hydroxypropyl cellulose), or HPMC (hydroxypropylmethylcellulose) and ,the like can be used.
- PVP polyvinylpyrrolidone
- Surfactants also act as suitable stabilizers such as polyoxyethylene Sforbitan monolaurate (Tween.TM. 20, Tween.TM. 80), pluronic F-68, Triton. TM. X-100, and sodium dodecyl sulfate (SDS), polysorbate or any other suitable surfactant can be selected.
- suitable stabilizers such as polyoxyethylene Sforbitan monolaurate (Tween.TM. 20, Tween.TM. 80), pluronic F-68, Triton. TM. X-100, and sodium dodecyl sulfate (SDS), polysorbate or any other suitable surfactant can be selected.
- Buffers are typically included in pharmaceutical formulations to maintain the pH of the formulation at a physiologically acceptable pH.
- the desirable pH for a formulation may also be affected by the active agent.
- suitable buffers include buffers derived from an acid such as phosphate, aconitic, citric, gluaric, malic, succinic and carbonic acid, alkali or alkaline earth salt of one of these acids, Tris buffer, histidine buffers, meglumine or any suitable buffer thereof.
- pH adjusting agents such as, but are not limited to sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, ammonium carbonate, hydrochloric acid, citric acid, lactic acid, phosphoric acid, sodium phosphate, sulfuric acid, and the like can also be used.
- excipients may also be added to the lyophilized preparations of the present inventions.
- excipients may include antioxidants, antimicrobials, cryostabilizers, or any other suitable pharmaceutically acceptable adjuvants thereof.
- the lyophilized product or the dried product shall be reconstituted and further diluted using suitable diluents.
- suitable diluents may include the following but are not limited to water, sodium chloride, dextrose, sugars, polyols, electrolytes or any other parenterally acceptable diluents and mixtures thereof.
- Cyclophosphamide is stable in its crystalline monohydrate form.
- the change of description of Cyclophosphamide monohydrate at various temperatures was studied by exposing the drug to different temperatures under constant vacuum and details are given in Tables 6 & 7:
- the formulation of the present invention preferably has a solvent or mixture of solvents.
- the inventors have surprisingly found by use of mixture of solvents with or without water, or mixture of solvent with water yielded best results.
- the monohydrate form present in the lyophilizate was evaluated in comparison with drug substance used in the process by way of following tests: Moisture Content and Water activity:
- the moisture content and water activity of the drug substance as well as the lyophilizate was checked to ensure the retention of the crystalline monohydrate form of the drug substance in the Lyophilizate.
- Water activity instruments measure the amount of free (sometimes referred to as unbound or active) water present in the sample and KF titration measures the total water in a sample. The values are tabulated in tables 9 and 10.
- X-Ray diffraction studies XRD was performed using Schimadzu XRD-7000 at following conditions:
- DSC was performed using TA-Q20J; °1 ⁇ 2 mg of sample was accurately weighed into aluminium pan. The pan was crimped and DSC was performed at a heating rate of 2°C/min from 25°C to 80°C under atmosphere of nitrogen.
- Lyophilized product was analyzed by HPLC for % purity and Assay. The result shows that the sample contains 0.27% impurities and was found to be 99.73% pure. By Assay HPLC was found to be 101% which is similar to the bulk solution assay prior to the lyophilization. These results show that during the lyophilization process sample was not degraded and crystalline monohydrate form is retained in final product. Cyclophosphamide monohydrate is official in USP and Ph.Eur. Both the monographs specify degradation analytical methods by Thin layer Chromatography. The TLC methods are time consuming and require usage of expensive USP reference impurity standards for comparison of Spots on TLC. These methods are not suitable for estimation of other degradation products or any source of contamination during manufacturing and storage of drug product.
- Mobile Phase- A 0.5ml of Triethylamine is diluted with in 1000ml of HPLC grade (Ultrapure) water and pH adjusted to 7.5 with dilute Orthophosphoric acid.
- Mobile Phase-B Mobile Phase-A and Acetonitrile are mixed in the ratio of (30:70) % v/v and degassed in a sonicator for about 10 min.
- Impurity-A 4 mg was weighed into a 100 ml volumetric flask and 50 ml of diluent added and sonicated for dissolution. The volume was made up with the diluent.
- Injection- Blank (as diluent), diluted standard for two times and test preparation in single into the liquid chromatographic system.
- the tailing factor for Impurity-A in standard solution is not more than 2.0
- Mobile Phase-B Water and Acetonitrile were mixed in the ratio of 20:80% v/v and degassed in a sonicator for about 1 Omin.
- Cyclophosphamide working standard was transferred into a 100 ml volumetric flask. 50 ml of diluent was added sonicated and volume was made up with diluent. 1ml of this solution was diluted to 10ml withvdiluent.
- the tailing factor for Cyclophosphamide peak in standard solution is not more than 2.0
- Impurity-C cannot be detected in HPLC UV detector because the impurity-C does not contain the necessary chromophoric, fluophoric or redox groups.
- this problem was overcome by inducing derivatization reaction. In post-column mode, the reaction is performed automatically by adding a derivatization reagent after separation, and before detection, by means of a second HPLC pump.
- Fluorescamine is used as dervitizing reagent for Impurity-C.
- the derivitized impurity-C was well detected at 380-nm.
- Mobile Phase -B Acetonitrile and HPLC grade (Ultrapure) water were mixed in the ratio of (90: 10) v/v and sonicated for 10 mintes for degassing.
- Procedure for post column derivatization technique A 'T' joint was connected to the column outlet of external pump and the other outlet of the column was connected to the HPLC detector. The mobile phase from HPLC pump and the mobile phase from external pump were mixed at the 'T' Joint connector and then pumped to the detector.
- the solvent mixture was prepared by taking acetone and TBA in a mixing vessel and the solution was cooled to 2-8°C. Cyclophosphamide was added to 80% of solvent mixture and stirred till completely dissolved followed by addition of water at 2-8°C. Volume was made up to 100% with solvent mixture and the bulk solution was filled into vials for lyophilisation.
- the lyophilization cycle parameters are mentioned in table 16.
- Example-2 S.No Ingredients Quantity mg Vial
- Acetonitrile and water were mixed and cooled to less than 10 ° C (Temperature range: -10 to 10 * C). Drug was added while temperature was maintained in the range mentioned. The solution was filtered and filled in vials to target fill volume and freeze dried.
- Acetonitrile and water were mixed and cooled to less than 10 " C (Temperature range: -10 to 10 ° C). Drug was added while temperature was maintained in the range mentioned. The solution was filtered and filled in vials to target fill volume and freeze dried.
- Acetone and water were mixed and cooled to less than 10 ° C (Temperature range: -10 to 10 ° C). Drug was added while temperature was maintained in the range mentioned. The solution was filtered and filled in vials to target fill volume and freeze dried.
- Acetone, Tertiary butanol and water were mixed and cooled to less tha 10 ° C (Temperature range: - 10 to 10 ° C). Drug was added while temperature was maintained in the range mentioned. The solution was filtered and filled in vials ' to target fill volume and freeze dried.
- Acetonitrile, Tertiary butanol and water were mixed and cooled to less than 10 ° C (Temperature range: -10 to 10 ° C). Drug was added while temperature was maintained in the range mentioned. The solution was filtered and filled in vials to target fill volume and freeze dried. i ;
- Acetonitrile, Tertiary butanol and water were mixed and cooled to less than 10 ° C (Temperature range: -10 to 10 ° C). Drug was added while temperature was maintained in the range mentioned. The solution was filtered and filled in vials to target fill volume and freeze dried.
- Acetonitrile, Tertiary butanol and water were mixed and cooled to less than 10 ° C (Temperature range: -10 to 10 ° C). Drug was added while temperature was maintained in the range mentioned. The solution was filtered and filled in vials to target fill volume and freeze dried.
- Cyclophosphamide was dissolved in cool acetone (Temperature range: -10 to 10 ° C). Tertiary butanol was added with continuous mixing. The solution was filtered and filled in vials to target fill volume and freeze dried.
- Cyclophosphamide was dissolved in cool acetone (Temperature range: -10 to I0 ° C). Tertiary butanol and water were added with continuous mixing. The solution was filtered and filled in vials to target fill volume and freeze dried.
- Example-11
- Cyclophosphamide was dissolved in cool acetone (Temperature range: -10 to 10 ° C). Tertiary butanol and water were added with continuous mixing. The solution was filtered and filled in vials to target fill volume and freeze dried.
- Cyclophosphamide was dissolved in cool acetone (Temperature range: -10 to 10 ° C). Tertiary butanol was added with continuous mixing. The solution was filtered and filled in vials to target fill volume and freeze dried.
- Cyclophosphamide was dissolved in cool acetone (Temperature range: - 10 to 10 ° C). Tertiary butanol was added with continuous mixing. The solution was filtered and filled in vials to target fill volume and freeze dried.
- Cyclophosphamide - was dissolved in cool acetone (Temperature range: -10 to 10 " C). Tertiary butanol and water were added with continuous mixing. The solution was filtered and filled in vials to target fill volume arid freeze dried.
- Cyclophosphamide was dissolved in cool Dimethylacetamide (Temperature range: -10 to 10 ° C) and water was added to the solution and mixed. The solution was filtered and filled in vials to target fill volume and freeze dried.
- Dimethylacetamide Tempoture range: -10 to 10 ° C
- the solvent mixture was prepared by taking acetonitrile and water in a mixing vessel and the solution was cooled to 2-8°C. Cyclophosphamide was added to 80% of solvent mixture and stirred well, until the drug is completely dissolved at 2-8°C. Volume was made up to 100% with solvent mixture and the bulk solution was filled into vials for lyophilization.
- the lyophilization cycle parameters are mentioned in below table 18:
- mannitol was dissolved in required quantity of water in a mixing vessel and cooled to 10°C- 15°C.
- Cyclophosphamide was dissolved in 80% of required quantity of Tertiary butanol. Mannitol solution was added to the drug solution and stirred at 10°C-15°C to get a uniform solution. Volume was made up to 100% with Tertiary butanol and the bulk solution was filled into vials for lyophihsation. The sample was then freeze dried.
- mannitol was dissolved in required quantity of water in a mixing vessel and was cooled to 10°C-15°C.
- Cyclophosphamide was dissolved in 80% of required quantity of Acetone. Mannitol solution was added to the drug solution and stirred at 10°C-15°C to get a unif
- mannitol was dissolved in required quantity of water in a mixing vessel and was cooled to 10°C-15°C.
- Cyclophosphamide was dissolved in 80% of required quantity of Acetonitrile. Mannitol solution was added to the drug solution and stirred at 10°C-15°C to get a uniform solution. Volume was made up to 100% with Acetonitrile and the bulk solution was filled into vials for lyophihsation. The sample was then freeze dried.
Abstract
The process for producing lyophilized compositions of cyclophosphamide monohydrate, wherein the process does not need rehydration step. The lyophilization is carried out in presence of solvent or mixture of solvent. The compositions of the present invention have greater stability and uniformity.
Description
Novel lyopliilizcd compositions of Cyclophosphamide
Background of the invention
Cyclophosphamide is a synthetic antineoplastic drug chemically related to the nitrogen mustards and has the following structure:
The chemical name of cyclophosphamide is 2-[bis(2-chloroethyI)amino]tetrahydro-2H- 1 ,3,2-oxazaphosphorine 2-oxide monohydrate. The compound along with related novel cyclic phosphoric acid ester amides was disclosed and claimed in U.S patent 3,018,302.
Cyclophosphamide comprises of monohydrate and anhydrous forms. The monohydrate is a stable form but under dry conditions (relative humidities of about 20% or less) the monohydrate begins to lose this water of hydration which can cause problems in manufacture. Hence maintaining the manufacturing and storage temperatures for this product is extremely important.
U.S patent 4,659,699 to Daniel et al. discloses the process for freeze drying of Cyclophosphamide. The two stage process described in the patent involves freeze drying of an aqueous solution of Cyclophosphamide to yield a hydrate of Cyclophosphamide. In the first stage, Cyclophosphamide is freeze dried with an excipient until the moisture content is less than 2% by weight. In the second stage, the freeze dried material is rehydrated until the moisture content of the product is in the critical range i.e 2-7% by weight. The process described in this patent requires the use of high quantity of excipients for maintaining the stability of the product.
U.S patent 4,537,883 to Alexander et al. discloses various lyophilizates of Cyclophosphamide. These lyophilizates are prepared by lyophilizing a solution of Cyclophosphamide and one or more excipients and rehydrating the product such that it contains about 4% moisture. The lyophilizates described in this patent used various excipients like mannitol, sodium bicarbonate, lactose, polyvinyl pyrrolidone (PVP), arginine, and tartaric acid.
U.S. patent 4,537,883 to Nageswara R. Palepu et al. discloses a stable rapidly dissolving lyophilized and hydrated composition of Cyclophosphamide with sodium bicarbonate. The disadvantages associated with the product described in this patent are the large size of the vials required for lyophilization and time taken to solubilise the product.
Cyclophosphamide is available as monohydrate in parenteral dosage formulation consisting of sterile packaged dry powder blend mixtures of drug and sodium chloride. The premixes were dissolved in water prior to administration. During the processing and storage of dry powder premix formulation, a glassiness and or stickiness could be acquired by the premix composition giving unattractive material with inferior solubility characteristics and decreased potency.
Hence there is a need to develop formulations of Cyclophosphamide overcoming the disadvantages of products and processes known in the art.
Summary of the invention
It is an object of the invention to develop lyophilized formulations of Cyclophosphamide using a process that does riot need rehydration step.
Another aspect of the present invention is to describe process for producing a stable lyophilized cyclophosphamide monohydrate formulation by using a suitable solvent or mixture of solvents in suitable proportions and optionally contains other excipients.
Another aspect of the present invention is to develop formulations of Cyclophosphamide monohydrate with uniform hydrate integrity between the vials.
Another aspect of the present invention is to provide Cyclophosphamide formulations with improved stability and lesser time for reconstitution.
It is yet another object of the invention to provide a stability indicating analytical method to monitor drug product quality.
BRIEF DESCRIPTION OF THE DRAWINGS:
FIG. 1 shows the DSC thermogram of prelyophilizate comprising of Cyclophosphamide dissolved in mixture of Acetone-TBA-Water (35.17: 47.61 : 16.67%v/v).
FIG 2 depicts Diffractogram of Cyclophosphamide drug and lyophilized product.
FIG 3 depicts a DSC thermogram obtained for Cyclophosphamide drug and lyophilized product.
FIG 4 depicts an IR spectra obtained for Cyclophosphamide drug and lyophilized product. DETAILED DESCRIPTION OF THE INVENTION
The objective of the present invention is to prepare a stable lyophilized parenteral pharmaceutical compositions of cyclophosphamide monohydrate.
An aspect of the present invention relates to the process for producing a stable lyophilized cyclophosphamide monohydrate formulation by using a suitable solvent or mixture of solvents in suitable proportions and optionally contains other excipients.
Another aspect of the present invention is to describe lyophilization process for producing pharmaceutical compositions of cyclophosphamide monohydrate. A lyophilization process of cyclophosphamide injection comprises of following steps: (a) Dissolving or dispersing cyclophosphamide in organic solvents or mixtures thereof (b) Filling the solution or dispersion in vials (c) Freezing the solution or dispersion (d) drying.
Another aspect of the present invention is to develop formulations of Cyclophosphamide monohydrate with uniform hydrate integrity between the vials and improved stability and lesser time for reconstitution.
Another aspect of the present invention is to describe stability indicating analytical method to monitor drug product quality.
The invention involves forming stable monohydrate "in situ" during lyophilization without the need for a rehydration step as taught in the prior art. This aspect of the invention is achieved by (i) a proper selection of solvent system and/ or (ii) optimal process conditions during the lyophilization process.
The present invention discloses a process for manufacturing a lyophilized preparation of cyclophosphamide intended for use in parenteral administration. The pharmaceutical formulation of the invention comprises Cyclophosphamide monohydrate and at least one organic solvent or mixture of solvents to dissolve the drug. The solvent is later removed during the freeze drying process. The formulation additionally comprises water to facilitate the formation of the stable monohydrate form during lyophilization.
Freeze drying process involves removal of solvent from a frozen mass under reduced atmospheric pressure. In the context of this invention the term freeze drying, drying and Lyophilization shall be used interchangeably. Lyophilization helps stabilize pharmaceutical formulations by reducing the solvent component or components to levels that no longer support chemical reactions or biological growth. Since drying during lyophilization takes place at a low temperature, chemical decomposition is also reduced.
Annealing shall be defined as process of transient increase in product temperature from initial set point to higher or lower set point, and then bringing the product temperature back to original set point. Annealing can be done on product during different steps of freeze drying process.
Frozen mass shall be defined as a product kept at temperature where in the physical state of the product changes from liquid to semi solid mass or solid mass. In the context of the present invention a frozen mass shall also mean a product kept at a temperature lower than zero degrees centigrade.
Prelyophilizate shall mean a composition comprising cyclophosphamide dissolved or suspended in solvents and meant to be subjected to freeze drying. The prelyophilizate may comprise suitable pharmaceutically acceptable excipient selected from list of excipients as described in the present invention" The excipients or drug shall be in dissolved or suspended form in the solvent mixture.
As used herein, the term "freeze-dried formulation" or "Lyophilizate" shall be defined as a dried product obtained as a result of freeze drying or lyophilization or drying process using a freeze dryer.
Freeze drying apparatus comprises of a chamber, condenser, and vacuum system with programmable features to control temperature and vacuum during drying process. The equipment optionally may have solvent trap.
The injectable formulations of the present invention comprises pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier or excipient can be selected from solvent, bulking agent, complexing agents, preservatives, anti-oxidants, stabilizers, tonicity modifiers or any other suitable adjuvant thereof.
As used herein the term "solvent" refers to the liquid component of a formulation that is capable of dissolving or suspending one or more solutes. The term "solvent" can refer to a single solvent or a mixture of solvents. The solvent, as mentioned, can be any liquid in which the material dissolves or could be suspended; the solvent can be a single substance or a mixture of co-solvents. Depending on the formulation or the freeze-drying process, it may be desirable to include one or more organic solvents in the liquid formulation. Suitable solvents include the following, but are not limited to Acetone, Acetonitrile, Tertiary butanol, Methanol, Ethanol, Isopropyl alcohol, Ethylacetate, Toulene, Propyl acetate, Nitromethane, 1 ,4-Dioxane, Heptane, Methylcyclohexane, Formic acid, isopropyl acetate, 1 ,2-Dimethoxyethane, 1 , 1 ,2-Trichloroethene, Methylethyl ketone, Cyclohexane, Ethyl formate, Hexane, Tetrahydrofuran, Chloroform, Methyl acetate, 1 ,2-Dichloroethene, tert-Butylmethyl ether, Dichloromethane, Pentane, Ethyl ether, Sulfalone, Ethyleneglycol, Formamide, Tetralin, N-Methylpyrrolidone, Dimethyl sulfoxide, N,N-Dimethylacetamide, 1-Pentanol, 3-Methyl-l -butanol, Anisole, Ν,Ν-Dimethylformamide, 2-Ethoxyethanol, 1- Butanol, 2-Methoxyethanol, Cumen^ Buiyl acetate, 2-Methyl-l-propanol, Chlorobenzene, Acetic acid, 2-Butanol, Isobutyl acetate, 1-Propanol, Pyridine, Methylbutyl ketone, Methyl isobutyl ketone, Xylene, Dimethyl carbonate, Hexafluoroacetone, Chlorobutanol, Dimethyl sulfone, carbon tetrachloride, tetrahydropyran, dioxane, trioxane and other cyclic mono-, di- and tri-ethers, propylene glycol (PG), polyethylene glycol, glycerine. The solvent system may additionally comprise water. Mixtures of solvents selected are used in a suitable proportion and suitable quantity to achieve desirable effect.
The purpose of the bulking agent is to provide bulk to the formulation and enhance cake formation. Bulking agents include saccharides, preferably monosaccharides or oligosaccharides, sugar alcohols, and mixtures thereof. Suitable bulking agents include the following, but are not limited to mannitol, sodium chloride, glucose, sucrose, lactose, trehalose, dextrose, maltose, sorbitol, dextran, raffinose, PVP, histidine, amino acids such as glycine, arginine, aspartic acid and the like.
Tonicity modifier can also be optionally added to the formulation. Suitable tonicity modifiers include the following, but are not limited to mannitol, dextrose, sucrose, glycine, glycerol, sodium chloride and the like.
Stabilizing agents are typically added to a formulation to improve stability of the formulation. Suitable examples of stabilizing agents include cryoprotectants, lyoprotectants, crystallization inhibitors or any other suitable stabilizer thereof. Suitable stabilizers include the following, but are not limited to Saccharides, including monosaccharides such as glucose, disaccharides such as sucrose (glucose+fructose), lactose (glucose+galactose), maltose (glucose+glucose), and trehalose (alpha-D- glucopyranosyl alpha-D-glucopyranoside), and polysaccharides such as dextran (polysaccharide containing glucose monomers, Crystallization inhibitors such as PVP (polyvinylpyrrolidone), HPC (hydroxypropyl cellulose), or HPMC (hydroxypropylmethylcellulose) and ,the like can be used. Surfactants also act as suitable stabilizers such as polyoxyethylene Sforbitan monolaurate (Tween.TM. 20, Tween.TM. 80), pluronic F-68, Triton. TM. X-100, and sodium dodecyl sulfate (SDS), polysorbate or any other suitable surfactant can be selected.
Buffers are typically included in pharmaceutical formulations to maintain the pH of the formulation at a physiologically acceptable pH. The desirable pH for a formulation may also be affected by the active agent. Examples of suitable buffers include buffers derived from an acid such as phosphate, aconitic, citric, gluaric, malic, succinic and carbonic acid, alkali or alkaline earth salt of one of these acids, Tris buffer, histidine buffers, meglumine or any suitable buffer thereof. pH adjusting agents such as, but are not limited to sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, ammonium carbonate, hydrochloric acid, citric acid, lactic acid, phosphoric acid, sodium phosphate, sulfuric acid, and the like can also be used.
Other excipients may also be added to the lyophilized preparations of the present inventions. Such excipients may include antioxidants, antimicrobials, cryostabilizers, or any other suitable pharmaceutically acceptable adjuvants thereof.
The lyophilized product or the dried product shall be reconstituted and further diluted using suitable diluents. Suitable diluents may include the following but are not limited to water, sodium chloride, dextrose, sugars, polyols, electrolytes or any other parenterally acceptable diluents and mixtures thereof.
Selection of solvent system and ratios
The solubility of Cyclophosphamide monohydrate in various solvents was checked. The quantity of solvent consumed for dissolving lOOmg of Cyclophosphamide monohydrate is given below:
Water 2.45ml
Acetonitrile 0.5ml
Acetone 0.4 ml
Ethanol 0.5ml
Tertiary butyl alcohol 0.5ml
Dimethyacetamide 2.0ml
Lyophilization. of Cyclophosphamide with different solvent systems
The investigators found surprising results that Cyclophosphamide monohydrate was obtained without rehydration step when Cyclophosphamide was freeze dried in presence of solvents.
Binary solvent mixtures were evaluated for lyophilization of Cyclophosphamide for injection.
Solvent systems used for the study are given below in Table- 1 :
Table 1 : Binary solvent Mixtures used for Lyophilization
NA: Not Applicable
The above mentioned solvent mixture ratios were lyophilized without rehydration step and the results of lyophilizate are given below
Table 2: Results of Binary solvent Mixtures used for Lyophilization
Observations & Conclusion:
From the analytical data it was observed that the water content was found to be within the acceptable range for monohydrate (5.7% w/w to 7.5%w/w) whereas the solvent levels are elevated.
Freeze drying of Cyclophosphamide using mixture of solvents:
Solvent mixtures of Acetone-Acetonitrile-Water and Acetone-Tertiary Butyl Alcohol- Water were evaluated to establish the suitability in lyophilization. The results are tabulated in table 3.
Table 3: Results after lyophilization with Acetone-Acetonitrile- Water and Acetone-TBA- Water:
*Not applicable
From the analytical results it is evident that Cyclophosphamide when freeze dried using mixture of Acetone: Acetonitrile: Water solvent mixture resulted in high residual solvent content and water content whereas the solvent system containing Acetone: TBA: Water showed low residual solvent content and significantly high water content.
The proportions of constituents of the solvent mixture was optimized by varying the % of water in the solvent system varying from about 7.8% v/v to 16.6% v/v to evaluate the effect of water on the drying Acetone, TBA and Water. The results are tabulated in table 4:
Table 4: Results of solvent mixture proportions on the lyophilizate:
The data in the above table shows that the level of residual solvent content in the lyophilizate was reduced by varying the proportions of water in the solvent mixture.
The impact of constituents of solvent composition used to dissolve cyclophosphamide was assessed by varying Acetone, TBA|;and Water in the pre-lyophilizate composition. The results are in the table 5.
Table 5 : Effect of solvent composition used to dissolve Cyclophosphamide on lyophilizate:
47.6
5 2 gms 35.17 16.66 9.9 71.0 6,53 1018 661
1
46.5
6 2 gms 34.88 18.60 10.1 78.7 6.37 792 538
1
45.4
7 2 gms 34.09 20.45 10.3 78.7 6.36 1575 428
5
44.4
8 2 gms 33.33 22.22 10.5 78.7 6.32 1730 387
4
43.4
9 2 gms 32.60 23.91 10.7 78.7 6.46 2010 437
7
33.3
10 2 gms 25.00 41.66 13.0 75.2 6.57 1 122 706
3
From above it is evident that residual solvent content, and target water content in the lyophilizate are within acceptable range.
Optimisation of process conditions
Cyclophosphamide is stable in its crystalline monohydrate form. The change of description of Cyclophosphamide monohydrate at various temperatures was studied by exposing the drug to different temperatures under constant vacuum and details are given in Tables 6 & 7:
Table 6: Description of Cyclophosphamide monohydrate at different temperatures at lOOOmtorr process vacuum:
The results indicate that physical stability or description of Cyclophosphamide is susceptible to temperature and vacuum. At higher temperatures and vacuum, Cyclophosphamide monohydrate loses water and melts. When it starts losing its water molecule, the physical description changes from powder to sticky mass or liquid, hence selection of the process conditions (like temperature, vacuum etc) is critical for lyophilization process so as to obtain monohydrate form. The selection of process conditions that result in insitu formation of monohydrate form of Cyclophosphamide are also dependent on composition of pre-lyophilizate.
The formulation of the present invention preferably has a solvent or mixture of solvents. The inventors have surprisingly found by use of mixture of solvents with or without water, or mixture of solvent with water yielded best results.
Evaluation of process conditions for Drying
The drug solution was transferred into sample pan and sealed with lid. DSC Q2000 was purged with nitrogen. Sample was cooled from 25°C to -50°C and heated from -50°C to 25°C at the rate of 1.5°C/min.
From the DSC thermogram of pre-lyophilizate as shown in FIG 1 it was observed that melt of frozen mass started at -32.80°C and complete melt was observed at -20.53°C. So, to enhance the crystallization, for controlled removal of water and to produce a uniform hydrate insitu during the process, the temperature of product during the drying process was kept on hold for -18°C for removal of water and TBA. Duration of hold at -18°C and 600 mtorr is important for insitu formation of Cyclophosphamide monohydrate and effective removal of excess TBA. This was evaluated by varying the duration of hold at -18°C at 600mtorr pressure during drying process as given in table 8:
Table 8: Analysis results of lyophilizate by varying the duration of hold at -18°C, 600 mtorr: ^
*Note: The total volume in all of above compositions was 9.9mL
The results showed that residual solvent content reduced in the lyophilizate with in hold time while retaining the water content of insitu monohydrate obtained.
Evaluation of Lyophilizate:
The monohydrate form present in the lyophilizate was evaluated in comparison with drug substance used in the process by way of following tests:
Moisture Content and Water activity:
The moisture content and water activity of the drug substance as well as the lyophilizate was checked to ensure the retention of the crystalline monohydrate form of the drug substance in the Lyophilizate. Water activity instruments measure the amount of free (sometimes referred to as unbound or active) water present in the sample and KF titration measures the total water in a sample. The values are tabulated in tables 9 and 10.
Table 9: Water content results of Drug substance and Lyophilizate
Table 10: Water activity results for Drug substance and Lyophilizate
Results for moisture content as well as the water activity were similar for the drug substance as well as the lyophilizate confirming that the crystalline monohydrate form of the API was retained in the lyophilized product. Crystalline monohydrate form contains 5.7 to 6.8% of water which is in agreement with the results obtained in table 6 to confirm that the lyophilizate is a stable monohydrate.
X-Ray diffraction studies:
XRD was performed using Schimadzu XRD-7000 at following conditions:
X-ray Tube: Cu (1.54060 A)
Voltage: 45.0 kV
Current: 40.0 mA
Scan Range: 2.5000 <-> 49.9980 deg
Step Size: 0.0170 deg
Count Time: 0.51 sec
Slit DS: 1 .00 deg
SS: 1.00 deg
RS: 0.15 mm
The diffractograms of drug substance and lyophilizate as shown in FIG 2; are comparable confirming that lyophilizate is a monohydrate form.
DSC studies
DSC was performed using TA-Q20J; °½ mg of sample was accurately weighed into aluminium pan. The pan was crimped and DSC was performed at a heating rate of 2°C/min from 25°C to 80°C under atmosphere of nitrogen.
The DSC thermograms of drug substance and lyophilizate are similar as shown in FIG 3. IR Studies:
1 to 2 mg of sample being examined was triturated with 300mg to 400mg of dried Potassium bromide. The sample was then scanned using a FT-IR spectrophotometer (Nicolet IS, Therm'oscientific).
The IR spectra of drug substance and lyophilizate are similar as shown in FIG 4. Analytical evaluations
Lyophilized product was analyzed by HPLC for % purity and Assay. The result shows that the sample contains 0.27% impurities and was found to be 99.73% pure. By Assay HPLC was found to be 101% which is similar to the bulk solution assay prior to the lyophilization. These results show that during the lyophilization process sample was not degraded and crystalline monohydrate form is retained in final product.
Cyclophosphamide monohydrate is official in USP and Ph.Eur. Both the monographs specify degradation analytical methods by Thin layer Chromatography. The TLC methods are time consuming and require usage of expensive USP reference impurity standards for comparison of Spots on TLC. These methods are not suitable for estimation of other degradation products or any source of contamination during manufacturing and storage of drug product.
Thus there is a need to develop stability indicating HPLC methods for monitoring quality of drug substance and drug product throughout the shelf life. The investigators developed novel HPLC analytical methods where in the polarity of mobile phase was gradually changed in order to separate the major degradation products on single Chromatographic run.
phosphate
HPLC method for estimation of Impurity-A:
Mobile Phase- A: 0.5ml of Triethylamine is diluted with in 1000ml of HPLC grade (Ultrapure) water and pH adjusted to 7.5 with dilute Orthophosphoric acid.
Mobile Phase-B: Mobile phase-A and Acetonitrile are mixed in the ratio of (30:70) % v/v and degassed in a sonicator for about 10 min.
Preparation of Diluent: Mobile Phase-A is used as diluent and maintained at temperature about 2-8°C in the refrigerator.
Typical chromatographic conditions:
Column Kinetex C-18 (100mm x 4.6 mm), 2.6μηι , Wave length 195nm
Flow rate 0.5 mL/min
Column oven Temperature 25±2°C
Sample cooling rack 5±1°C
Injection volume ΙΟΟμΙ,
Runtime
Table 12: chromatographic conditions for detection of Impurity A
Preparation of standard solution:
Preparation of Impurity-A solution: 0.2% Level
4 mg of Impurity-A was weighed into a 100 ml volumetric flask and 50 ml of diluent added and sonicated for dissolution. The volume was made up with the diluent.
Preparation of Sample solution: (20mg/ml)
100 mg of Cyclophosphamide was weighed into a 5 ml volumetric flask and 3 ml of diluent was added and sonicated. Volume was made up with the diluent.
Procedure:
Injection- Blank (as diluent), diluted standard for two times and test preparation in single into the liquid chromatographic system.
System Suitability Parameters:
• The tailing factor for Impurity-A in standard solution is not more than 2.0
• The USP theoretical plates for Impurity-A is not less than 2000
• The relative standard deviation for two replicate injections is not more than
10.0%
Detection of Impurity B and D
Mobile Phase-A: 1ml of Orthophosp¾oric acid is mixed in 1000ml of water (0.1%) and ø
degassed in sonicator for about lOmin.
Mobile Phase-B: Water and Acetonitrile were mixed in the ratio of 20:80% v/v and degassed in a sonicator for about 1 Omin.
Preparation of Diluent: HPLC grade (Ultrapure) water maintained at temperature about 2-
8°C.
Typical chromatographic conditions:
Column Inertsil-ODS 3, 25cm x 4.6 mm, 5μπι (LI)
Wave length 195nm
Flow rate 0.5 mL/min
Column oven Temperature 25±2°C
Sample cooling rack 5±1°C
Injection volume ΙΟΟμί
Runtime 75 minutes
Sample concentration 20 mg/mL
Gradient program:
Table 13 : chromatographic conditions for detection of Impurity B and D
Preparation of standard solution: (0.2% level)
40.0 mg of Cyclophosphamide working standard was transferred into a 100 ml volumetric flask. 50 ml of diluent was added sonicated and volume was made up with diluent. 1ml of this solution was diluted to 10ml withvdiluent.
Preparation of Sample:
100 mg sample was transferred into a 5 ml volumetric flask, 3 ml was added and sonicated and made to volume with diluent.
Procedure:
Injection- the Blank (as diluent), diluted standard for two replicate injections and a single test preparation into the liquid Chromatographic system.
System Suitability Parameters:
1. The tailing factor for Cyclophosphamide peak in standard solution is not more than 2.0
2. The USP theoretical plates for Cyclophosphamide peak is not less than 4000
3. The relative standard deviation for two replicate injections is not more than 10.0%
Calculation:
Blank peaks are disregarded and all impurity peaks and Cyclophosphamide peaks are integrated. Peak below 0.05% is disregarded.
Table 14: Cyclophosphamide Impurities and their retention times
• RRT - Relative retention time
# RRF- Relative retention factor
Detection of Impurity C
Impurity-C cannot be detected in HPLC UV detector because the impurity-C does not contain the necessary chromophoric, fluophoric or redox groups. However, this problem was overcome by inducing derivatization reaction. In post-column mode, the reaction is performed automatically by adding a derivatization reagent after separation, and before detection, by means of a second HPLC pump.
Fluorescamine is used as dervitizing reagent for Impurity-C. The derivitized impurity-C was well detected at 380-nm.
Mobile Phase -A: 1.712 lg of di-sodium hydrogen phosphate (0.01M) was transferred in 1000ml of HPLC grade (Ultrapure) water and mixed well, pH 10.5 adjusted with diluted Sodium hydroxide.
Mobile Phase -B: Acetonitrile and HPLC grade (Ultrapure) water were mixed in the ratio of (90: 10) v/v and sonicated for 10 mintes for degassing.
Preparation of Diluent: HPLC grade (Ultrapure) water maintained at temperature about 2- 8°C is used as diluent.
Typical chromatographic conditions:
Column Purospher Star RP18, (250mm x 4.6 mm) 5μηι (LI) Wave length 380nm .
Flow rate 1.0 mL/min
Column oven Temperature 25±2°C
Sample cooling rack 5±1°C
Injection volume ΙΟΟμΙ,
Runtime 35 minutes
Sample concentration 20 mg/mL Gradient program:
Table 15: Chromatographic conditions for detection of Impurity C
External Pump conditions:
Connector : 'Τ' Joint
Flow rate <: l .Oml/min
Mobile Phase for external pump: Accurately weighed 80mg of Fluroscamine derivitizating reagent was transferred to a 200ml volumetric flask and 100ml of Acetonitrile was added and the volume was made up volume with Acetonitrile and mixed well.
Preparation of Impurity-C: (~10ppm)-0.06% Level
About 5 mg of Cyclophosphamide Impurity-C was accurately weighed and transferred into a 10 ml volumetric flask and about 5 ml of water was added. The contents were sonicated and the volume was made up with water and further mixed well. Subsequently, 1ml of this solution was diluted to 50ml with water and mixed well.
Procedure for post column derivatization technique: A 'T' joint was connected to the column outlet of external pump and the other outlet of the column was connected to the
HPLC detector. The mobile phase from HPLC pump and the mobile phase from external pump were mixed at the 'T' Joint connector and then pumped to the detector.
The following examples further describe certain specific aspects and embodiments of the present invention and demonstrate the practice and advantages thereof. It is to be understood that the examples are given by way of illustration only and are not intended to limit the scope of the invention in any manner.
Examples
Example-1
The solvent mixture was prepared by taking acetone and TBA in a mixing vessel and the solution was cooled to 2-8°C. Cyclophosphamide was added to 80% of solvent mixture and stirred till completely dissolved followed by addition of water at 2-8°C. Volume was made up to 100% with solvent mixture and the bulk solution was filled into vials for lyophilisation. The lyophilization cycle parameters are mentioned in table 16.
Table- 16: Freeze drying cycle process parameters:
Freezing -45 60 R 12.7
-
Freezing -45 180 H 15.7
Primary Drying -45 60 R 50 16.7
Primary Drying -45 420 H 50 23.7
Primary Drying -30 180 R 600 26.7
Primary Drying -45 60 R 600 27.7
Primary Drying -18 $ 120 R 600 29.7
Primary Drying -42 60 R 600 30.7
Primary Drying -18 120 R 600 32.7
Primary Drying -42 60 R 600 33.7
Primary Drying -18 120 R 600 35.7
Primary Drying -42 60 R 600 36.7
Primary Drying -18 120 R 600 38.7
Primary Drying -42 60 R 600 39.7
Primary Drying -18 120 R 600 41.7
Primary Drying -42 60 R 600 42.7
Primary Drying -18 120 R 600 44.7
Primary Drying -42 60 R 600 45.7
Primary Drying -18 120 R 600 47.7
Primary Drying -42 60 R 600 48.7
Primary Drying -18 120 R 600 50.7
Primary Drying -42 60 R 600 51.7
28 Primary Drying -18 120 R 600 53.7
29 Primary Drying -18 680 H 600 65.0
30 Primary Drying -42 60 R 800 66.0
31 Primary Drying -42 300 H 800 71.0
The product was evaluated for water content, Solvent content and reconstitution time. Results are tabulated in table 17.
Table 17: Analytical results of lyophilizate:
As is evident from the above results, the formation of monohydrate and the reconstitution time are consistent even at different strengths.
The procedures described herein are adapted to prepare other compositions described below:
Example-2
S.No Ingredients Quantity mg Vial
1. Cyclophosphamide 2000
2. Acetonitrile: Water (30:70) Q.s to 16.0 mL
Acetonitrile and water were mixed and cooled to less than 10°C (Temperature range: -10 to 10*C). Drug was added while temperature was maintained in the range mentioned. The solution was filtered and filled in vials to target fill volume and freeze dried.
Example-3
Acetonitrile and water were mixed and cooled to less than 10"C (Temperature range: -10 to 10°C). Drug was added while temperature was maintained in the range mentioned. The solution was filtered and filled in vials to target fill volume and freeze dried.
Example-4
Acetone and water were mixed and cooled to less than 10°C (Temperature range: -10 to 10°C). Drug was added while temperature was maintained in the range mentioned. The solution was filtered and filled in vials to target fill volume and freeze dried.
Example-5
Acetone, Tertiary butanol and water were mixed and cooled to less tha 10°C (Temperature range: - 10 to 10°C). Drug was added while temperature was maintained in the range mentioned. The solution was filtered and filled in vials' to target fill volume and freeze dried.
Example-6
Acetonitrile, Tertiary butanol and water were mixed and cooled to less than 10°C (Temperature range: -10 to 10°C). Drug was added while temperature was maintained in the range mentioned. The solution was filtered and filled in vials to target fill volume and freeze dried. i;
Example-7
Acetonitrile, Tertiary butanol and water were mixed and cooled to less than 10°C (Temperature range: -10 to 10°C). Drug was added while temperature was maintained in the range mentioned. The solution was filtered and filled in vials to target fill volume and freeze dried.
Example-8
Acetonitrile, Tertiary butanol and water were mixed and cooled to less than 10°C (Temperature range: -10 to 10°C). Drug was added while temperature was maintained in the range mentioned. The solution was filtered and filled in vials to target fill volume and freeze dried.
ExampIe-9
Cyclophosphamide was dissolved in cool acetone (Temperature range: -10 to 10°C). Tertiary butanol was added with continuous mixing. The solution was filtered and filled in vials to target fill volume and freeze dried.
Example-10:
Cyclophosphamide was dissolved in cool acetone (Temperature range: -10 to I0°C). Tertiary butanol and water were added with continuous mixing. The solution was filtered and filled in vials to target fill volume and freeze dried.
Example-11 :
Cyclophosphamide was dissolved in cool acetone (Temperature range: -10 to 10°C). Tertiary butanol and water were added with continuous mixing. The solution was filtered and filled in vials to target fill volume and freeze dried.
Example-12:
Cyclophosphamide was dissolved in cool acetone (Temperature range: -10 to 10°C). Tertiary butanol was added with continuous mixing. The solution was filtered and filled in vials to target fill volume and freeze dried.
Examnle-13;
Cyclophosphamide was dissolved in cool acetone (Temperature range: - 10 to 10°C). Tertiary butanol was added with continuous mixing. The solution was filtered and filled in vials to target fill volume and freeze dried.
Example-14
Cyclophosphamide - was dissolved in cool acetone (Temperature range: -10 to 10"C). Tertiary butanol and water were added with continuous mixing. The solution was filtered and filled in vials to target fill volume arid freeze dried.
Examnle-15
Lyophihzation experiments were performed using solvents that had lower vapour pressure than water for example: Dimethyl acetamide and Dimethylsulfoxide. It was found that, the use of these solvents did not result in stable lyophilizate. if
Composition:
Cyclophosphamide was dissolved in cool Dimethylacetamide (Temperature range: -10 to 10°C) and water was added to the solution and mixed. The solution was filtered and filled in vials to target fill volume and freeze dried.
Example-16
The solvent mixture was prepared by taking acetonitrile and water in a mixing vessel and the solution was cooled to 2-8°C. Cyclophosphamide was added to 80% of solvent mixture and stirred well, until the drug is completely dissolved at 2-8°C. Volume was made up to 100% with solvent mixture and the bulk solution was filled into vials for lyophilization. The lyophilization cycle parameters are mentioned in below table 18:
Table 18: Lyophilization Cycle
Freezing 15.166
7 -50 200 H -
Freezing 18.50
8 Primary Drying -50 60 R 50 19.50
9 Primary Drying -50 180 H 50 22.50
10 Primary Drying -30 120 R 600 24.50
1 1 Primary Drying -50 60 R 600 25.50
12 Primary Drying -30 120 R 600 27.50
13 Primary Drying -50 60 R 600 28.50
14 Primary Drying -30 120 R 600 30.50
15 Primary Drying -50 60 R 600 31.50
16 Primary Drying -30 120 R 600 33.50
17 Primary Drying 180 H 600 36.50
18 Primary Drying -fb 960 H 600 52.50
19 Primary Drying -30 120 H 350 54.50
Results: Water content (%) was 5.8% and Solvent Content (ppm) was 2500.
Initially mannitol was dissolved in required quantity of water in a mixing vessel and cooled to 10°C- 15°C. In another mixing vessel Cyclophosphamide was dissolved in 80% of required quantity of Tertiary butanol. Mannitol solution was added to the drug solution and stirred at 10°C-15°C to get a uniform solution. Volume was made up to 100% with
Tertiary butanol and the bulk solution was filled into vials for lyophihsation. The sample was then freeze dried.
Example 18
Initially mannitol was dissolved in required quantity of water in a mixing vessel and was cooled to 10°C-15°C. In another mixing vessel Cyclophosphamide was dissolved in 80% of required quantity of Acetone. Mannitol solution was added to the drug solution and stirred at 10°C-15°C to get a unif|fcni'"'solution. Volume was made up to 100% with Acetone and the bulk solution was filled into vials for lyophihsation. The sample was then freeze dried.
Example 19
Initially mannitol was dissolved in required quantity of water in a mixing vessel and was cooled to 10°C-15°C. In another mixing vessel Cyclophosphamide was dissolved in 80% of required quantity of Acetonitrile. Mannitol solution was added to the drug solution and stirred at 10°C-15°C to get a uniform solution. Volume was made up to 100% with Acetonitrile and the bulk solution was filled into vials for lyophihsation. The sample was then freeze dried.
Example 20
Initially sodium chloride was dissolved in required quantity of water in a mixing vessel. In another mixing vessel solvent mixture was prepared by taking acetone and acetonitrile and the solution was cooled to 2-8°C. Cyclophosphamide was added to 80% of solvent mixture and stirred well, until the drug is completely dissolved at 2-8°C. Sodium chloride solution was added to solvent mixture and stirrbcHo get a uniform solution. Volume was made up to 100% with solvent mixture and the bulk solution was filled into vials for lyophilisation. The sample was then freeze dried.
Example 21
Initially sodium chloride was dissolved in required quantity of water in a mixing vessel. In another mixing vessel 80% of required quantity of Acetone was taken cooled to 2-8°C. Cyclophosphamide was added to above solvent and stirred well, until the drug is completely dissolved at 2-8°C. Sodium chloride solution was added to drug solution and stirred to get uniform solution. Volume was made up to 100% with Acetone and the bulk solution was filled into vials for lyophilisation. The sample was then freeze dried.
Claims
1. A composition comprising lyophilized cyclophosphamide monohydrate where in lyophilization process is carried out without a rehydration step.
2. A composition comprising lyophilized cyclophosphamide monohydrate where in lyophi ization is carried out in presence of solvent or mixtures of solvents.
3. The composition according to claim 2, wherein the solvent is selected from group comprising Acetone, Acetonitrile, Tertiary butanol, Methanol, Ethanol, Isopropyl alcohol, Ethylacetate, Toluene, Propyl acetate, Nitromethane, 1,4-Dioxane, Heptane, Methylcyclohexane, Formic acid, isopropyl acetate, 1,2- Dimethoxyethane, 1 , 1 ,2-Trichloroethene, Methylethyl ketone, Cyclohexane, Ethyl formate, Hexane, Tetrahydrofuran, Chloroform, Methyl acetate, 1,2- Dichloroethene, tert-Butylmethyl ether, Dichloromethane, Pentane, Ethyl ether, Sulfalone, Ethyleneglycol, Formamide, Tetralin, N-Methylpyrrolidone, Dimethyl sulfoxide, N,N-Dimethylacef¾mide, 1-Pentanol, 3 -Methyl- 1 -butanol, Anisole, N,N- Dimethylformamide, 2-Ethoxyethanol, 1 -Butanol, 2-Methoxyethanol, Cumene, Butyl acetate, 2-Methyl-l-propanol, Chlorobenzene, Acetic acid, 2-Butanol, Isobutyl acetate, 1 -Propanol, Pyridine, Methylbutyl ketone, Methyl isobutyl ketone, Xylene, Dimethyl carbonate, Hexafluoroacetone, Chlorobutanol, Dimethylsulfone, carbon tetrachloride and tetrahydropyran.
4. The composition according to claim 2, comprising of a mixture of two or more solvents selected from Acetone, Acetonitrile, Tertiary butanol, Methanol, Ethanol, Isopropyl alcohol, Ethylacetate, Toluene, Propyl acetate, Nitromethane, 1 ,4- Dioxane, Heptane, Methylcyclohexane, Formic acid, isopropyl acetate, 1,2- Dimethoxyethane, 1 , 1 ,2-Trichloroethene, Methylethyl ketone, Cyclohexane, Ethyl formate, Hexane, Tetrahydrofuran, Chloroform, Methyl acetate, 1,2- Dichloroethene, tert-Butylmethyl ether, Dichloromethane, Pentane, Ethyl ether, Sulfalone, Ethyleneglycol, Formamide, Tetralin, N-Methylpyrrolidone, Dimethyl sulfoxide, Ν,Ν-Dimethylacetamide, 1-Pentanol, 3 -Methyl- 1 -butanol, Anisole, N,N- Dimethylformamide, 2-Ethoxyethanol, 1 -Butanol, 2-Methoxyethanol, Cumene, Butyl acetate, 2-Methyl-l-propanol, Chlorobenzene, Acetic acid, 2-Butanol,
Isobutyl acetate, 1-Propanol, Pyridine, Methylbutyl ketone, Methyl isobutyl ketone, Xylene, Dimethyl carbonate, Hexafluoroacetone, Chlorobutanol, Dimethylsulfone, Carbon tetrachloride and tetrahydropyran.
5. The composition according to claim 2, comprising of mixture of two or more solvents where in atleast one solvent shall have vapor pressure higher than or equal to water selected from Toluene, Propyl acetate, Nitromethane, 1 ,4-Dioxane, 2- Propanol , Heptane, Methylcyclohexane, Ethanol , Formic acid, Isopropyl acetate , 1 ,2-Dimethoxyethane, 1, 1,2-Trichloroethene, Methylethyl ketone, Ethyl acetate, Acetonitrile, Cyclohexane, Ethyl formate, Methanol, Hexane, Tetrahydrofuran, Chloroform, Methyl acetate, 1 ,2-Dichloroethene, Acetone, tert-Butylmethyl ether, Dichloromethane, Pentane, Ethyl ether and atleast one solvent shall have vapor pressure lower than or equal to water and selected from Tertiary butanol, Sulfalone, Ethylene glycol, Formamide, Tetralin, N-Methylpyrrolidone, Dimethyl sulfoxide, Ν,Ν-Dimethylacetamide, lrPentanol, 3-Methyl-l -butanol, Anisole, N,N- Dimethylformamide, 2-EthcfKyethanol, 1 -Butanol, 2-Methoxy ethanol, Cumene, Butyl acetate, 2-Methyl-l-propanol, Chlorobenzene, Acetic acid, 2-Butanol, Isobutyl acetate, 1 -Propanol, Pyridine, Methylbutyl ketone, Methyl isobutyl ketone, Dimethyl carbonate, Hexafluoroacetone, carbon tetrachloride and tetrahydropyran.
6. The composition according to claim 2, comprising of mixture of two or more solvents, wherein atleast one solvent is tertiary butanol, and other solvent or mixture of solvents shall be selected from Acetone, Acetonitrile, Methanol, Ethanol, Isopropyl alcohol, Ethylacetate, Toluene, Propyl acetate, Nitromethane, 1 ,4-Dioxane, Heptane, Methylcyclohexane, Formic acid, isopropyl acetate, 1,2- Dimethoxyethane, 1 ,1,2-Trichloroethene, Methylethyl ketone, Cyclohexane, Ethyl formate, Hexane, Tetrahydrofuran, Chloroform, Methyl acetate, 1 ,2- Dichloroethene, tert-Butylmethyl ether, Dichloromethane, Pentane, Ethyl ether, Sulfalone, Ethyleneglycol, Formamide, Tetralin, N-Methylpyrrolidone, Dimethyl sulfoxide, N,N-Dimethylacetamide, 1-Pentanol, 3-Methyl-l -butanol, Anisole, N,N- Dimethylformamide, 2-Ethoxyethanol, 1 -Butanol, 2-Methoxyethanol, Cumene, Butyl acetate, 2-Methyl-l-propanol, Chlorobenzene, Acetic - acid, 2-Butanol, Isobutyl acetate, 1 -Propanol, Pyridine, Methylbutyl ketone, Methyl isobutyl ketone,
Xylene, Dimethyl carbonate, Hexafluoroacetone, Chlorobutanol, Dimethylsulfone, carbon tetrachloride and tetrahydropyran.
7. The composition according to claim 2, where in solvent shall be selected from Acetone, Acetonitrile, Methanol, Ethanol, Isopropyl alcohol, Toluene, Propyl acetate, Nitromethane, Heptane, Methylcyclohexane, isopropyl acetate, 1,2- Dimethoxyethane, 1, 1 ,2-Trichloroethane, Methylethyl ketone, Ethyl acetate, Ethyl formate, Hexane, Tetrahydrofuran, Chloroform, Methyl acetate, 1 ,2- Dichloroethene, tert-Butylmethyl ether, Dichloromethane, Pentane, Ethyl ether, Tetralin, Ν,Ν-Dimethylacetamide, 1 -Pentanol, 3-Methyl-l -butanol, Anisole, N,N- Dimethylformamide, 2-Ethoxyethanol, 1-Butanol, 2-Methoxy ethanol, Cumene, Butyl acetate, 2-Methyl- l-propanol, Chlorobenzene, 2-Butanol, Isobutyl acetate, 1 - Propanol, Pyridine, Ethyleneglycol, Formamide, N-Methylpyrrolidone, Dimethyl sulfoxide, Sulfalone, acetic acid, 1,4-Dioxane, Formic acid, Methylbutyl ketone, Cyclohexane, Methyl isobutyl, ketone, Hexafluoroacetone, tetrahydropyran and shall have freezing point below -5°C
8. The composition according to claim 2, where in the solvent mixture additionally comprises water.
9. The composition according to claim 2, wherein lyophilization is carried out using the solvent combinations selected from Acetone and Acetonitrile, Acetone and Tertiary butanol, Acetonitrile and Tertiary butanol, Isopropyl alcohol and Tertiary butanol, Methanol and Tertiary butanol, Ethanol and Tertiary butanol, Methanol and Isopropyl alcohol, Ethanol and Isopropyl alcohol, Acetonitrile and Isopropyl alcohol.
10. The compositions according to claim 9, wherein solvent mixture additionally comprises water.
1 1. The composition according to claim 2, comprising of solvent or mixture of solvents atleast 25% volume by volume.
12. The compositions according to claim 7, where in solvent mixture additionally comprises water ranging between 0.5% to 60% volume by volume.
13. A process of lyophilizing cyclophosphamide for injection without involving rehydration step.
14. A [yophilisation process for manufacturing Cyclophosphamide injection wherein the process is carried out using organic solvents, a mixture of organic solvents or a mixture of organic solvents and water.
15. A lyophilization process of cyclophosphamide injection comprising of following steps:' (a) Dissolving or dispersing cyclophosphamide in organic solvents or mixtures thereof (b) Filling the solution or dispersion in vials (c) Freezing the solution or dispersion (d) drying.
16. The process of lyophilization of cyclophosphamide according to claim 15, wherein freezing is performed at temperatures below -12°C.
17. The process of freezing according to claim 15, further comprises of one or more annealing steps.
8. The process of lyophilization of cyclophosphamide according to claim 15, wherein drying is performed at temperatures between -50°C and -5°C.
19. The process of lyophilization of cyclophosphamide according to claim 15, where in vacuum used for drying steps*shall be selected between 10 mtorr and 1500mbar.
20. The vacuum range according to claim 19, shall be selected between lOmtorr to 800mtorr.
21. The process of lyophilization of cyclophosphamide that shall comprise of atleast one annealing step with temperature ranging between -10°C and -90°C during freezing, and drying steps.
22. A lyophilized product of cyclophosphamide prepared according to claim 15, comprising of water content in finished product ranging between 5.5% to 8.5%w/w and residual solvent content within acceptable ICH limits for the respective solvent.
23. A lyophilized product of cyclophosphamide prepared according to claim 2 having reconstitution time of less than 60 seconds
24. A lyophilized product of cyclophosphamide prepared according to claim 15, having reconstitution time of less than 60 seconds
25. A lyophilized product of cyclophosphamide prepared according to claim 15, comprising of one or more pharmaceutically acceptable carriers or excipients
26. A lyophilized product of cyclophosphamide prepared according to claim 2, comprising of one or more pharmaceutically acceptable excipients
27. The process of lyophilization of cyclophosphamide according to claim 15, comprising of atleast one of the last three drying steps at a temperature less than or equal +5°C.
28. The process of lyophilization of cyclophosphamide according to claim 27,
comprising of performing secondary drying at a temperature below -15°C for a duration of atleast 2 hours.
29. A lyophilized composition of Cyclophosphamide obtained by the process of claim 1.
30; A reverse phased HPLC method for quantitative analysis of impurities in preparations containing Cyclophosphamide.
31. A reversed phase HPLC method comprising of use of post column derivatization technique for quantitative analysis of impurities in preparations containing Cyclophosphamide.
32. A reversed phase HPLC method described in Claim 30 used for quantitative analysis consisting of: &
(a) Mobile Phase-A comprising of triethylamine dissolved in water at a pH of 7.5
(b) Mobile Phase-B comprising of atleast 40% of Acetonitrile mixed with Mobile phase-A
(c) The temperature of diluted sample maintained between 2-25°C
(d) The chromatographic conditions comprising of C-18 column having a particle size of 2.6μπι or lesser, and flow rate of atleast 0.5mL/min, and run time of atleast 30 minutes, at a temperature of 25±2°C.
33. A chromatographic separation of impurity-A using chromatographic conditions according to claim 32, and with a gradient program comprising of combining mobile phase-A and mobile phase-b in a programmed manner over a run time of atleast 15 minutes
34. A reversed phase HPLC method according to Claim 30, used for quantitative analysis consisting of:
a) Mobile Phase-A comprising of orthophosphoric acid dissolved in water
b) Mobile Phase-B comprising of atleast 10% of Acetonitrile mixed with Mobile phase-A
c) The temperature of diluted sample maintained between 2-25°C
d) The chromatographic conditions comprising of C-18 column having a particle size of 5μιτι or lesser, and flow rate of atleast 0.5mL/min, and run time of atleast 30 minutes, at a temperature of 25±2°C
35. A chromatographic separation of impurity-B and impurity-D using chromatographic conditions according to claim 34, and with a gradient program comprising of combining mobile phase-A and mobile phase-b in a programmed manner over a run time of atleast 15 minutes.
36. A reversed phase HPLC method according to Claim 31, used for quantitative analysis using post column derivatization technique for determination of impurity- C consisting of:
(a) Using a derivatizing agent Fluorescamine
(b) Mobile Phase-A comprising ofdisodium hydrogen phosphate buffer at pH 10.5
(c) Mobile Phase-B comprisingJbf atleast 50% of Acetonitrile mixed with Mobile phase-A
(d) The temperature of diluted sample maintained between 2-25°C
(e) The chromatographic conditions comprising of C-18 column having a particle size of 5μιτι or lesser, and flow rate of atleast 0.5mL/min, and run time of atleast 15 minutes, at a temperature of 25±2°C.
37. A chromatographic separation of impurity-C using chromatographic conditions according to claim 35, with a gradient program comprising of combining mobile phase-A and mobile phase-b in a programmed manner over a run time of atleast 15 minutes.
38. A lyophilized product of cyclophosphamide prepared according to claim 1, having a shelf life of atleast 1 year when stored below 25°C.
39. A lyophilized product of cyclophosphamide prepared according to claim 2, having a shelf life of atleast 1 year when stored below 25°C.
40. A lyophilized product of cyclophosphamide prepared according to claim 1,
comprising of suitable pharmaceutically acceptable carriers or excipients
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/439,079 US20150290226A1 (en) | 2012-10-29 | 2013-07-29 | Novel lyophilized compositions of cyclophosphamide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
INCH44832012 | 2012-10-29 | ||
IN4483/CHE/2012 | 2012-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014068585A1 true WO2014068585A1 (en) | 2014-05-08 |
Family
ID=50626595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2013/000469 WO2014068585A1 (en) | 2012-10-29 | 2013-07-29 | Novel lyophilized compositions of cyclophosphamide |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014068585A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104535689A (en) * | 2015-01-04 | 2015-04-22 | 合肥国轩高科动力能源股份公司 | Gas chromatography detection method of N-mtthyl pyrrolidone (NMP) content in lithium ion battery pole pieces |
WO2016005962A3 (en) * | 2014-07-11 | 2016-03-17 | Dr. Reddy’S Laboratories Limited | Stable liquid formulations of cyclophosphamide and processes |
WO2015171460A3 (en) * | 2014-05-09 | 2016-04-21 | AuroMedics Pharma LLC | Formulations of cyclophosphamide liquid concentrate |
WO2016132270A1 (en) * | 2015-02-16 | 2016-08-25 | Leiutis Pharmaceuticals Pvt Ltd | Stable ready to use cyclophosphamide liquid formulations |
US10149857B2 (en) | 2017-03-09 | 2018-12-11 | Ampac Fine Chemicals Llc | Lyophilized cyclophosphamide composition and methods of preparation thereof |
WO2019199076A1 (en) * | 2018-04-13 | 2019-10-17 | 한국유나이티드제약 주식회사 | Method for preparing lyophilized cyclophosphamide without using organic solvent |
CN111781287A (en) * | 2020-07-21 | 2020-10-16 | 宁波卫生职业技术学院 | Method for detecting residual solvent in medical non-woven fabric product |
US10849916B2 (en) | 2014-07-11 | 2020-12-01 | Dr. Reddys Laboratories Limited | Stable liquid formulations of cyclophosphamide and its impurities |
WO2021005544A1 (en) | 2019-07-10 | 2021-01-14 | Intas Pharmaceuticals Ltd. | Stable oral composition of cyclophosphamide |
CN115462369A (en) * | 2022-09-29 | 2022-12-13 | 安徽省立医院(中国科学技术大学附属第一医院) | Vitrification freezing exosome preservation method |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4537883A (en) * | 1982-11-12 | 1985-08-27 | Mead Johnson & Company | Lyophilized cyclophosphamide |
EP0394045A2 (en) * | 1989-04-20 | 1990-10-24 | Erbamont, Inc. | Cyclophosphamide lyophilizates |
US5036060A (en) * | 1988-07-25 | 1991-07-30 | Fujisawa Usa, Inc. | Cyclophosphamide |
US5066647A (en) * | 1989-04-20 | 1991-11-19 | Erbamont, Inc. | Cyclophosphamide - alanine lyophilizates |
US5418223A (en) * | 1993-05-20 | 1995-05-23 | Erbamont, Inc. | Method for lyophilization of cyclophosphamide and product |
CN101330905A (en) * | 2005-11-18 | 2008-12-24 | 赛多斯有限责任公司 | Lyophilization process and products obtained thereby |
-
2013
- 2013-07-29 WO PCT/IN2013/000469 patent/WO2014068585A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4537883A (en) * | 1982-11-12 | 1985-08-27 | Mead Johnson & Company | Lyophilized cyclophosphamide |
US5036060A (en) * | 1988-07-25 | 1991-07-30 | Fujisawa Usa, Inc. | Cyclophosphamide |
EP0394045A2 (en) * | 1989-04-20 | 1990-10-24 | Erbamont, Inc. | Cyclophosphamide lyophilizates |
US5066647A (en) * | 1989-04-20 | 1991-11-19 | Erbamont, Inc. | Cyclophosphamide - alanine lyophilizates |
US5418223A (en) * | 1993-05-20 | 1995-05-23 | Erbamont, Inc. | Method for lyophilization of cyclophosphamide and product |
CN101330905A (en) * | 2005-11-18 | 2008-12-24 | 赛多斯有限责任公司 | Lyophilization process and products obtained thereby |
Non-Patent Citations (1)
Title |
---|
ZHOU, XINLI ET AL.: "Research on annealing mechanism in freeze-drying process of pharmaceuticals", CHEMICAL ENGINEERING, vol. 33, no. 6, December 2005 (2005-12-01), CHINA, pages 4 - 7 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015256331B2 (en) * | 2014-05-09 | 2020-03-12 | AuroMedics Pharma LLC | Formulations of Cyclophosphamide liquid concentrate |
WO2015171460A3 (en) * | 2014-05-09 | 2016-04-21 | AuroMedics Pharma LLC | Formulations of cyclophosphamide liquid concentrate |
WO2016005962A3 (en) * | 2014-07-11 | 2016-03-17 | Dr. Reddy’S Laboratories Limited | Stable liquid formulations of cyclophosphamide and processes |
US11382923B2 (en) | 2014-07-11 | 2022-07-12 | Dr. Reddy's Laboratories Limited | Stable liquid formulations of cyclophosphamide and processes to prepare the same |
US10849916B2 (en) | 2014-07-11 | 2020-12-01 | Dr. Reddys Laboratories Limited | Stable liquid formulations of cyclophosphamide and its impurities |
CN104535689A (en) * | 2015-01-04 | 2015-04-22 | 合肥国轩高科动力能源股份公司 | Gas chromatography detection method of N-mtthyl pyrrolidone (NMP) content in lithium ion battery pole pieces |
WO2016132270A1 (en) * | 2015-02-16 | 2016-08-25 | Leiutis Pharmaceuticals Pvt Ltd | Stable ready to use cyclophosphamide liquid formulations |
US10993952B2 (en) | 2015-02-16 | 2021-05-04 | Leiutis Pharmaceuticals Pvt. Ltd. | Stable ready to use cyclophosphamide liquid formulations |
US10149857B2 (en) | 2017-03-09 | 2018-12-11 | Ampac Fine Chemicals Llc | Lyophilized cyclophosphamide composition and methods of preparation thereof |
US10307431B2 (en) | 2017-03-09 | 2019-06-04 | Ampac Fine Chemicals Llc | Lyophilized cyclophosphamide composition and methods of preparation thereof |
KR20190119881A (en) * | 2018-04-13 | 2019-10-23 | 한국유나이티드제약 주식회사 | A method for preparation of organic solvent-free lyophilized cyclophosphamide |
KR102224781B1 (en) | 2018-04-13 | 2021-03-09 | 한국유나이티드제약 주식회사 | A method for preparation of organic solvent-free lyophilized cyclophosphamide |
WO2019199076A1 (en) * | 2018-04-13 | 2019-10-17 | 한국유나이티드제약 주식회사 | Method for preparing lyophilized cyclophosphamide without using organic solvent |
US11707434B2 (en) | 2018-04-13 | 2023-07-25 | Korea United Pharm. Inc. | Method for preparing organic solvent-free lyophilized cyclophosphamide |
WO2021005544A1 (en) | 2019-07-10 | 2021-01-14 | Intas Pharmaceuticals Ltd. | Stable oral composition of cyclophosphamide |
CN111781287A (en) * | 2020-07-21 | 2020-10-16 | 宁波卫生职业技术学院 | Method for detecting residual solvent in medical non-woven fabric product |
CN115462369A (en) * | 2022-09-29 | 2022-12-13 | 安徽省立医院(中国科学技术大学附属第一医院) | Vitrification freezing exosome preservation method |
CN115462369B (en) * | 2022-09-29 | 2023-09-22 | 安徽省立医院(中国科学技术大学附属第一医院) | Vitrification frozen exosome preservation method |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014068585A1 (en) | Novel lyophilized compositions of cyclophosphamide | |
KR101536781B1 (en) | Caspofungin formulations | |
JP3503943B2 (en) | Crystalline amifostine composition and method for its preparation and use | |
FI117924B (en) | Methods for the preparation of crystalline amifostine compositions | |
US10869848B2 (en) | Carmustine pharmaceutical composition | |
JP2007526329A (en) | Freeze-drying method to improve excipient crystallization | |
AU2017364135B2 (en) | Pharmaceutical parenteral formulation containing carglumic acid | |
US20150094293A1 (en) | Solid forms of ceftolozane | |
EP2958554B1 (en) | Stable compositions of bendamustine | |
US20150290226A1 (en) | Novel lyophilized compositions of cyclophosphamide | |
CA2894935A1 (en) | Novel crystalline forms of ceftaroline fosamil | |
JP2019202127A (en) | Formulation having reduced n-formylpiperidine content and/or lyo cake with inhibited collapse or contraction | |
EP3856151B1 (en) | Lyophilisate of treosulfan | |
WO2021009595A1 (en) | Cyclophosphamide injectable composition and methods for producing same | |
EA043302B1 (en) | TREOSULPHAN LYOPHYLISATE | |
EP3908258A1 (en) | A process for preparation of a stable pharmaceutical composition of bortezomib | |
EP3031811A1 (en) | Malic acid esters of bortezomib | |
WO2020064816A1 (en) | Solution comprising treosulfan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13851343 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14439079 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13851343 Country of ref document: EP Kind code of ref document: A1 |